Loading...

TRML TOURMALINE BIO INC Investor Conferences 8-K Filing

TRML

TRML

TOURMALINE BIO INC

(TRML)

2024 8-K

Show Summary

Show Summary

Product Expansion

Financial Statements

Financial Results

Corporate Presentation

Investor Day Updates

Financial Results

Management Change

Bylaw Amendments

Earnings Reports

Appointment of CFO

Annual Meeting Results

Earnings Report

Underwriting Agreement

Merger and Name Change

Press Release and Corporate...

Appointment of Clay Siegall

Resignation of Director

Merger Transaction

Management Changes

Merger and Name Change

Special Meeting Results

Special Dividend Announcement

Merger Agreement

Update on Investor Presenta...

Merger Agreement

Merger Agreement

Management Changes

Reduction in Force

Regulation FD Disclosure

Financial Condition and Res...

External Links:

Tourmaline Bio, Inc. announced key updates during its Investor Day, including over-enrollment in its Phase 2 TRANQUILITY trial with 143 patients, and plans for a Phase 2 trial for abdominal aortic aneurysm, expecting topline data in Q2 2025.

AI Assistant

TOURMALINE BIO INC

2024

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.